共 28 条
[1]
Xu XF(2021)Global, regional, and national incidence and year lived with disability for benign prostatic hyperplasia from 1990 to 2019 Am J Mens Health 15 15579883211036786-157
[2]
Foo KT(2017)Pathophysiology of clinical benign prostatic hyperplasia Asian J Urol 4 152-1439
[3]
Füllhase C(2016)Transurethral resection of the prostate Urologe A 55 1433-804
[4]
Parsons JK(2020)Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020 J Urol 204 799-703
[5]
Welliver C(2017)Technique considerations and complication management in transurethral resection of the prostate and photoselective vaporization of the prostate Transl Androl Urol 6 695-31
[6]
Helo S(2005)High-power thulium fiber laser ablation of urinary tissues at 1.94 microm J Endourol 19 25-341
[7]
McVary KT(2010)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 8 336-980
[8]
Fried NM(2020)Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews Emerg Med J 37 387-1898
[9]
Murray KE(2020)Functional outcomes of transurethral thulium laser enucleation versus bipolar transurethral resection for benign prostatic hyperplasia over a period of 12 months: a prospective randomized study Int J Urol 27 974-315
[10]
Moher D(2020)Clinical outcome of transurethral enucleation of the prostate using the 120-W thulium laser (Vela™ XL) compared to bipolar transurethral resection of the prostate (TURP) in aging male Aging (Albany NY) 12 1888-1802

